Human epidermal growth factor receptor 2 (HER2) positivity can serve to guide adjuvant trastuzumab therapy. 1 Several clinical trials have documented the effect of adjuvant trastuzumab on the improvement in prognosis for HER2-positive breast cancer. [2] [3] [4] However, trastuzumab administration can be associated with cardiotoxicity. 5 We read the article entitled ''Acute cardiotoxic effects of adjuvant trastuzumab treatment and its relation with oxidative stress'' with interest. 6 These findings are important because they may allow the prediction and preventive treatment of the cardiotoxic effects of trastuzumab. 7, 8 It is known that almost 1 in 4 patients treated with trastuzumab have troponin elevations as well as some degree of cardiotoxicity. 9 We suggest that in the future, such studies should also determine troponin I, high-sensitivity C-reactive protein, and N-terminal prohormone of B-type natriuretic peptide levels. Because pulmonary fibrosis and respiratory failure can aggravate heart failure and have been reported after radiation of the chest, 10 do you have any data regarding this complication? Did the patients have any lung function tests before or after trastuzumab medication? Mediastinal irradiation can also lead to long-term cardiac complications with a possible synergistic effect with chemotherapy. 4, 5 This may be more obvious with left chest irradiation. Was there a difference, in terms of cardiotoxicity, between right and left irradiation? This study addresses an important field and may help prevent trastuzumab cardiotoxicity.
